BICD2 is the second human homolog discovered to the Drosophila Bicaudal-D protein that forms part of the cytoskeleton and mediates the correct sorting of mRNAs for oocyte- and axis-determining factors during oogenesis. Similar to the highly homologous protein BICD1, BICD2 can bind to dynein-dynactin complex, primarily through the dynamitin subunit of dynactin. The C-terminus of BICD2 targets the protein to the Golgi complex while the N-terminal domain of BICD2 co-immunoprecipitates with cytoplasmic dynein, suggesting BICD2 plays a role in the dynein-dynactin interaction on the surface of membranous organelles. Mice engineered to overexpress the BICD2 amino terminal domain in neurons developed amyotrophic lateral sclerosis (ALS)-like features such as Golgi fragmentation, neurofilament swelling in proximal axons, etc., suggesting that impaired dynein/dynactin function may explain some of the pathological features observed in ALS patients. This BICD2 antibody will not cross-react with BICD1.

Abbiotec坚信与我们的科学家，客户，合作者和分销商社区建立牢固而有意义的合作伙伴关系。我们通过研究合作与社区分享我们的想法，并通过有益于生命科学界的创新和有用的产品来回馈青睐。我们欢迎有关研究或产品创意的讨论，我们将努力为此类讨论提供最有利和最机密的环境。Abbiotec利用专有技术和特殊资源开发自己的产品，以实现高质量的生产和控制。我们还从其他合作伙伴（例如个人科学家，大学外发许可部门和其他生物技术公司）获得产品和想法的许可。被许可的技术或想法被开发为商业产品，并通过我们的营销和销售网络在全球范围内销售。